Identification of the Metabolic Protein ATP5MF As a Potential Therapeutic Target of TNBC

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2024 Oct 14

PMID 39402579

Authors

Kaiyan Chen

Yingchun Wu

Linfeng Xu

Changyong Wang

Jinqiu Xue

Affiliations

Soon will be listed here.

Abstract

Background: Triple-negative breast cancer (TNBC), a distinct subtype of breast cancer, is characterized by its high invasiveness, high metastatic potential, proneness to relapse, and poor prognosis. Effective treatment regimens for non-BRCA1/2 mutation TNBC are still lacking. As a result, there is a pressing clinical necessity to develop novel treatment approaches for non-BRCA1/2 mutation TNBC.

Methods: For this research, the scRNA data was obtained from the GEO database, while the transcriptome data was obtained from the TCGA and METABRIC databases. Quality control procedures were conducted on single-cell sequencing data. and then annotation and the Copycat algorithm were applied for anlysis. Employing the high dimensional weighted gene coexpression network analysis (hdWGCNA) method, we analyzed the tumor epithelial cells from non-BRCA1/2 mutation TNBC to identify the functional module genes. PPI analysis and survival analysis were further emplyed to identify the key gene. siRNA-NC and siRNA-ATP5MF were transfected into two MDA-MB-231 and BT-549 TNBC cell lines. Cell growth was determined by CCK8 assay, colony formation and migration assay. Electron microscopy was used to examine the structure of mitochondria in cells. JC-1 staining was used to measure the potential of the mitochondrial membrane. A tumor xenograft animal model was established by injecting TNBC cells into nude mice. The animal model was usded to evaluated in vivo tumor response aftering ATP5MF silencing.

Results: Using hdWGCNA, we have identified 136 genes in module 3. After PPI and survival analysis, we have identified ATP5MF as a potential therapeutic gene. High ATP5MF expression was associated with poor prognosis of non-BRCA1/2 mutation TNBC. The high expression of ATP5MF in TNBC tissues was evaluated using the TCGA database and IHC staining of clinical TNBC specimens. Silencing ATP5MF in two TNBC cell lines reduced the growth and colony formation of TNBC cells in vitro, and hindered the growth of TNBC xenografts in vivo. Additionally, ATP5MF knockdown impaired mitochondrial functions in TNBC cells.

Conclusion: In summary, the metabolic protein ATP5MF plays a crucial role in the non-BRCA1/2 mutation TNBC cells, making it a potential novel diagnostic and therapeutic oncotarget for non-BRCA1/2 mutation TNBC.

References

Jiang Y, Ma D, Suo C, Shi J, Xue M, Hu X . Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell. 2019; 35(3):428-440.e5. DOI: 10.1016/j.ccell.2019.02.001. View

Luo L, Keyomarsi K . PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. Expert Opin Investig Drugs. 2022; 31(6):607-631. PMC: 9296104. DOI: 10.1080/13543784.2022.2067527. View

Subramanian A, Narayan R, Corsello S, Peck D, Natoli T, Lu X . A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell. 2017; 171(6):1437-1452.e17. PMC: 5990023. DOI: 10.1016/j.cell.2017.10.049. View

Dong J, Horvath S . Understanding network concepts in modules. BMC Syst Biol. 2007; 1:24. PMC: 3238286. DOI: 10.1186/1752-0509-1-24. View

Morabito S, Miyoshi E, Michael N, Shahin S, Martini A, Head E . Single-nucleus chromatin accessibility and transcriptomic characterization of Alzheimer's disease. Nat Genet. 2021; 53(8):1143-1155. PMC: 8766217. DOI: 10.1038/s41588-021-00894-z. View

Lee A . Location, location, location: regulation of breast cancer progression by the microenvironment. Breast Cancer Res. 2004; 6(6):279-80. PMC: 1064092. DOI: 10.1186/bcr957. View

Isakoff S, Mayer E, He L, Traina T, Carey L, Krag K . TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2015; 33(17):1902-9. PMC: 4451173. DOI: 10.1200/JCO.2014.57.6660. View

Langfelder P, Zhang B, Horvath S . Defining clusters from a hierarchical cluster tree: the Dynamic Tree Cut package for R. Bioinformatics. 2007; 24(5):719-20. DOI: 10.1093/bioinformatics/btm563. View

Kil Y, Risinger A, Petersen C, Mooberry S, Cichewicz R . Leucinostatins from spp. and spp. Demonstrate Selective Antiproliferative Effects in Cells Representing the Luminal Androgen Receptor Subtype of Triple Negative Breast Cancer. J Nat Prod. 2020; 83(6):2010-2024. PMC: 7704123. DOI: 10.1021/acs.jnatprod.0c00404. View

10.

Zueva A, Silchenko A, Rasin A, Malyarenko O, Kusaykin M, Kalinovsky A . Production of high- and low-molecular weight fucoidan fragments with defined sulfation patterns and heightened in vitro anticancer activity against TNBC cells using novel endo-fucanases of the GH107 family. Carbohydr Polym. 2023; 318:121128. DOI: 10.1016/j.carbpol.2023.121128. View

11.

Jia D, Park J, Jung K, Levine H, Kaipparettu B . Elucidating the Metabolic Plasticity of Cancer: Mitochondrial Reprogramming and Hybrid Metabolic States. Cells. 2018; 7(3). PMC: 5870353. DOI: 10.3390/cells7030021. View

12.

Lehmann B, Bauer J, Chen X, Sanders M, Chakravarthy A, Shyr Y . Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121(7):2750-67. PMC: 3127435. DOI: 10.1172/JCI45014. View

13.

Zhu Y, Jia H, Gao G, Pan G, Jiang Y, Li P . Mitochondria-acting nanomicelles for destruction of cancer cells via excessive mitophagy/autophagy-driven lethal energy depletion and phototherapy. Biomaterials. 2020; 232:119668. DOI: 10.1016/j.biomaterials.2019.119668. View

14.

Garrido-Castro A, Lin N, Polyak K . Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019; 9(2):176-198. PMC: 6387871. DOI: 10.1158/2159-8290.CD-18-1177. View

15.

Denkert C, Liedtke C, Tutt A, von Minckwitz G . Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2016; 389(10087):2430-2442. DOI: 10.1016/S0140-6736(16)32454-0. View

16.

Xu W, Zhang W, Zhao D, Wang Q, Zhang M, Li Q . Unveiling the role of regulatory T cells in the tumor microenvironment of pancreatic cancer through single-cell transcriptomics and experiments. Front Immunol. 2023; 14:1242909. PMC: 10518406. DOI: 10.3389/fimmu.2023.1242909. View

17.

Luo X, Gong X, Su L, Lin H, Yang Z, Yan X . Activatable Mitochondria-Targeting Organoarsenic Prodrugs for Bioenergetic Cancer Therapy. Angew Chem Int Ed Engl. 2020; 60(3):1403-1410. DOI: 10.1002/anie.202012237. View

18.

Park J, Vithayathil S, Kumar S, Sung P, Dobrolecki L, Putluri V . Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Rep. 2016; 14(9):2154-2165. PMC: 4809061. DOI: 10.1016/j.celrep.2016.02.004. View

19.

Zacksenhaus E, Shrestha M, Liu J, Vorobieva I, Chung P, Ju Y . Mitochondrial OXPHOS Induced by RB1 Deficiency in Breast Cancer: Implications for Anabolic Metabolism, Stemness, and Metastasis. Trends Cancer. 2017; 3(11):768-779. DOI: 10.1016/j.trecan.2017.09.002. View

20.

Choi J, Kim D, Jung W, Koo J . Metabolic interaction between cancer cells and stromal cells according to breast cancer molecular subtype. Breast Cancer Res. 2013; 15(5):R78. PMC: 3979011. DOI: 10.1186/bcr3472. View